COMBINED TELOMERASE INHIBITOR AND GEMCITABINE FOR THE TREATMENT OF CANCER
A method and kit for inhibiting the proliferation of cancer cells are disclosed, based on a combination of a gemcitabine and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with gemcitabine alone or the telomer...
Saved in:
Main Authors | , |
---|---|
Format | Patent |
Language | English French German |
Published |
12.06.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | A method and kit for inhibiting the proliferation of cancer cells are disclosed, based on a combination of a gemcitabine and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with gemcitabine alone or the telomerase inhibitor alone. Preferably, efficacy is supraadditive or synergistic in nature relative to the combined effects of the individual agents, with minimal exacerbation of side effects. |
---|---|
Bibliography: | Application Number: EP20180196347 |